The treatment landscape for liver cancer has shifted significantly in recent years, with immunotherapy combinations now replacing older targeted drugs as the standard first-line approach for advanced disease. The most notable recent development: in April 2025, the FDA approved a new immunotherapy combination of nivolumab plus ipilimumab for first-line treatment of unresectable or metastatic hepatocellular carcinoma (HCC), joining two other immunotherapy combinations already in use. These newer regimens are pushing median survival for advanced liver cancer past 19 months, roughly double what was achievable a decade ago.
How Treatment Depends on Stage
Liver cancer treatment isn’t one-size-fits-all. The approach your medical team recommends depends on a web of factors: the size and number of tumors, how well the liver is functioning overall, your general health, and whether the cancer has spread beyond the liver. The Barcelona Clinic Liver Cancer (BCLC) staging system, updated in 2025, is the most widely used framework for matching patients to therapies.
For very early-stage tumors, the updated guidelines now recognize several options for destroying tumors directly, including radiofrequency ablation, microwave ablation, targeted radiation, and radioembolization. For intermediate-stage disease, locoregional therapies that treat the tumor inside the liver remain central. For advanced cancer that can’t be surgically removed or has spread, systemic therapy with immunotherapy combinations is now the primary approach.
First-Line Immunotherapy Combinations
Three immunotherapy-based regimens are now recommended as first-line treatment for advanced HCC in patients with good liver function and reasonable overall fitness. Each pairs drugs that work on different parts of the immune system to help the body recognize and attack cancer cells.
The combination of atezolizumab plus bevacizumab was the first to demonstrate a clear survival advantage over sorafenib (the previous standard) in the IMbrave150 trial, delivering a median overall survival of 19.2 months. The second option, durvalumab plus tremelimumab, showed a median overall survival of 16.4 months in the HIMALAYA trial, also outperforming sorafenib. Long-term follow-up from HIMALAYA found that 25% of patients were still alive at four years, and those who responded to treatment maintained that response for a median of over 22 months.
The newest addition is nivolumab plus ipilimumab, which received FDA approval in April 2025 specifically for first-line use in advanced HCC. This combination pairs two immune checkpoint inhibitors that target different immune pathways, and its approval gives oncologists a third frontline option, particularly relevant for patients who may not be candidates for the other two regimens.
What Happens When First-Line Treatment Stops Working
One of the biggest challenges in liver cancer treatment right now is what to do when a patient’s cancer progresses after initial immunotherapy. All of the currently approved second-line drugs were originally tested against sorafenib, not against the newer immunotherapy combinations. That means there’s limited high-quality evidence guiding second-line decisions after immunotherapy failure.
In practice, patients who progress after first-line immunotherapy are typically switched to targeted drugs called tyrosine kinase inhibitors, including sorafenib, lenvatinib, cabozantinib, or regorafenib. Some are instead given a different immunotherapy. Early data suggests that patients who receive a different immunotherapy after failing first-line treatment may have longer survival (around 14.9 months) compared to those switched to a targeted drug alone (around 8.4 months), though these numbers come from observational data rather than head-to-head trials.
One combination that has been specifically tested in patients who progressed on first-line immunotherapy, regorafenib paired with pembrolizumab, showed modest results: only about 6% of patients saw their tumors shrink, though nearly half achieved stable disease where the cancer stopped growing for a time.
Advances in Radiation-Based Liver Treatments
Radioembolization, which delivers tiny radioactive beads directly into the blood vessels feeding a liver tumor, has seen meaningful refinements. The procedure uses yttrium-90 microspheres that lodge in the tumor’s blood supply and irradiate it from the inside. Recent improvements in how doctors calculate radiation doses and select patients have elevated radioembolization from an alternative option to a frontline choice in several clinical scenarios, particularly for patients with tumors confined to the liver who aren’t surgical candidates.
Experimental enhancements are also being developed. One approach pairs the radioactive beads with light-sensitive nanoparticles. The radiation emitted by yttrium-90 activates these particles, which then generate additional cancer-killing molecules. This effectively extends the treatment’s reach into parts of the tumor farther from where the beads settle. Other experimental combinations include delivering chemotherapy drugs or immune-boosting agents alongside the radioactive beads, though these remain in preclinical testing.
Personalized Cancer Vaccines
One of the most promising experimental approaches is a personalized anti-tumor vaccine designed to train the immune system to recognize a specific patient’s cancer. In a preliminary trial led by investigators at Johns Hopkins Kimmel Cancer Center, 36 patients with HCC received a personalized vaccine alongside pembrolizumab, an immune checkpoint inhibitor.
The results were encouraging: nearly one-third of patients saw their tumors shrink, roughly double the response rate typically seen with checkpoint inhibitor therapy alone. About 8% of patients had a complete response, meaning no detectable tumor remained. Side effects were mild, primarily injection site reactions, with no serious adverse events linked to the vaccine. A larger randomized trial is needed to confirm these findings, but the approach represents a genuinely new direction: instead of broadly activating the immune system, personalized vaccines aim to give it a precise target.
How to Think About These Options
The number of available treatments for liver cancer has expanded rapidly, but navigating them still comes down to a few key factors. Tumor stage and liver function are the primary drivers. A patient with a single small tumor and a well-functioning liver faces a completely different treatment pathway than someone with widespread disease or cirrhosis-related liver damage. The 2025 BCLC guidelines emphasize that factors beyond the tumor itself, including a patient’s other health conditions and overall fitness, should shape treatment choices.
For advanced disease, the practical difference between the three first-line immunotherapy combinations is nuanced. Atezolizumab plus bevacizumab has the longest track record and the highest median survival in trial data, but it includes bevacizumab, which carries a risk of bleeding, making it potentially unsuitable for patients with certain vascular conditions. The newer nivolumab plus ipilimumab approval provides an all-immunotherapy option that avoids that particular risk. Treatment selection increasingly involves weighing these trade-offs against each patient’s specific medical profile rather than following a single default protocol.